ThromboGenics Announces Half Year Results 2008

Posted on: Thursday, 28 August 2008, 12:01 CDT LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008. During the first half of 2008, ThromboGenics has achieved a... [read full story]                    

Add Comment
There are also 1 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies